ST6GAL1 and gastric cancer: For example, abnormal O-linked and N-linked glycosylation modifications, mediated by enzymes such as N-acetylgalactosaminyl-transferase 1 (GALNT1) and ST6 beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1), have been linked to the activation of the Wnt/β-catenin pathway and the development of trastuzumab-resistance in GC cells, respectively.24